Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: A review of medical devices complications in 3172 patients

Medical Devices: Evidence and Research

Volumn 2, Issue 1, 2009, Pages 31-40

  Bacchetti, Stefano ^a   Pasqual, Enricomaria ^a   Crozzolo, Elena ^a   Pellarin, Alessandra ^a   Cagol, Pier Paolo ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Colorectal cancer; Intra arterial hepatic chemotherapy; Liver metastases; Loco regional treatments; Medical devices

Indexed keywords

CATHETERS; CHEMOTHERAPY; DISEASES; PATHOLOGY; PUMPS; SURGERY;

ADJUVANT TREATMENT; COLORECTAL CANCER; CONTINUOUS INFUSIONS; IMPLANTABLE PUMPS; LIVER METASTASIS; LOCO-REGIONAL TREATMENTS; MEDICAL DEVICES; SELECTION CRITERIA;

LIVER;

CAMPTOTHECIN; CISPLATIN; FLOXURIDINE; FLUOROURACIL; IRINOTECAN; MITOMYCIN; MITOMYCIN C; OXALIPLATIN;

ARTERY CATHETERIZATION; ARTERY THROMBOSIS; CANCER COMBINATION CHEMOTHERAPY; CATHETER; CATHETER THROMBOSIS; CLINICAL EVALUATION; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG INFUSION; GASTRODUODENAL ARTERY; HEPATIC ARTERY; HUMAN; LAPAROTOMY; LIVER METASTASIS; MINIPUMP; REVIEW; RISK ASSESSMENT; SURGICAL INFECTION; VASCULAR ACCESS;

EID: 77953396091     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/mder.s4036     Document Type: Review

References (138)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Kemeny N, Eid A, Stockman J, et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol. 2005;91:97-101.
3. Homsi J, Garrett CR. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. Cancer Control. 2006;13:42-47.
4. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016.
5. Hunt TM, Flowerdew AD, Birch S, et al. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg. 1990;77:779-782.
6. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397-1400.
7. Rothbarth J, van de Velde CJ. Treatment of liver metastases of colorectal cancer. Ann Oncol. 2005;16:144-149.
8. Cady B, Stone MD, McDermott WV, et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastasis. Arch Surg. 1992;127:561-569.
9. Taylor I. Colorectal cancer and the liver. Ann R Surg Engl. 1997; 79:315-318.
10. Lehnert T, Pfitzenmaier J, Hinz U, et al. Surgery for local recurrence or distant metastases in patients aged 75 years or older. Eur J Surg Oncol. 1998;24:418-422.
11. Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol. 1999;26:514-523.
12. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397-406.
13. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125-134.
14. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
15. Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007;246:806-814.
16. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007; 246:183-191.
17. Van Ooijen B, Wiggers T, Meijer S, et al. Hepatic resections for colorectal metastases in The Netherlands. A multiinstitutional 10-year study. Cancer. 1992;70:28-34.
18. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-520.
19. Beard SM, Holmes M, Price C, et al. Hepatic resection for colorectal liver metastases: a cost-effectiveness analysis. Ann Surg. 2000;232:763-776.
20. Andres A, Majno PE, Morel P, et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol. 2008;15:134-143.
21. Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg. 1992;216:493-504.
22. Gayowski T, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994;116:703-711.
23. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
24. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766.
25. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
26. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;3:51-64.
27. Polk W, Fong Y, Karpeh M, Blumgart L. A technique for the use of cryosurgery to assist hepatic resection. J Am Coll Surg. 1995;180:171-176.
28. Adam R, Akpinar E, Johann M, et al. Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg. 1997;225:39-50.
29. Seifert J, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg. 1998;228:201-208.
30. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221:159-166.
31. McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg. 2006;93:1192-1201.
32. Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol. 2007;14:1161-1169.
33. McGrane S, McSweeney SE, Maher MM. Which patients will benefit from percutaneous radiofrequency ablation of colorectal liver metastases? Critically appraised topic. Abdom Imaging. 2008;33:48-53.
34. Garden OJ, Rees M, Poston GJ, et al. Guidelines for resection of colorectal cancer liver metastases. Gut. 2006;55:1-8.
35. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
36. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;25:1041-1047.
37. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;1:23-30.
38. Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. Cancer. 2008;112:1879-1891.
39. Chari RS, Helton WS, Marsh RD. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement by Bartlett et al. Ann Surg Oncol. 2006;13:1293-1295.
40. Kohnoe S, Endo K, Yamamoto M, et al. Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. Surgery. 2002;131(1):128-134.
41. Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol. 2003;14:1537-1542.
42. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23:4881-4887.
43. Ensminger WD. A role for hepatic-directed chemotherapy in colorectal liver metastases. J Clin Oncol. 2005;23:4815-4817.
44. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395-1403.
45. Fiorentini G, Cantore M, Rossi S, et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo. 2006;20:707-709.
46. Carnaghi C, Santoro A, Rimassa L, et al. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. Invest New Drugs. 2007;25:479-485.
47. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15:219-226.
48. Hafstrom L, Engaras B, Holmberg SB, et al. Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A randomized clinical trial. Cancer. 1994;74:2749-2756.
49. Laffer UT, Metzger U. Intraportal chemotherapy for colorectal hepatic metastases. World J Surg. 1995;19:246-251.
50. Allen-Mersh TG, Glover C, Fordy C, et al. Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. Eur J Surg Oncol. 2000;26:468-473.
51. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720.
52. Piedbois P, Zelek L and Cherqui D. Chemotherapy of nonoperable colorectal liver metastases. Hepatogastroenterology. 2001;48:711-714.
53. Kemeny N, Ron I. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol. 1999a;26:524-535.
54. Skitzki JJ, Chang AE. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol. 2002;11:123-135.
55. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361:368-373.
56. Clavien PA, Selzner N, Morse M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery. 2002;131:433-442.
57. Selzner N, Pestalozzi BC, Kadry Z, et al. Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. Br J Surg. 2006;93:587-592.
58. Tanaka K, Shimada H, Ueda M, et al. Perioperative complications after hepatectomy with or without intra-arterial chemotherapy for bilobar colorectal cancer liver metastases. Surgery. 2006;139:599-607.
59. Campbell KA, Burns RC, Sitzmann JV, et al. Regional chemotherapy devices:effect of experience and anatomy on complications. J Clin Oncol. 1993;11:822-826.
60. Fordy C, Burke D, Earlam S, et al. Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Br J Cancer. 1995;72:1023-1025.
61. Doughty JC, Keogh G, Mc Ardle S. Methods of replacing blocked hepatic artery catheters. Br J Surg. 1997;84:618-619.
62. Civalleri D, DeCian F, Pellicci R, et al. Differential device performances for hepatic arterial chemotherapy: a technical report on totally implantable pumps and ports for both continuous and bolus infusion. Eur Surg Res. 1998;30:26-33.
63. Van Riel JM, Groeningen CJ, Albers S, et al. Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. Ann Oncol. 2000;11:1563-1570.
64. O'Connel MJ, Nagorney DM, Bernath AM, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol. 1998;16:2528-2533.
65. Bonetti A. Hepatic artery infusion for liver metastases from colorectal cancer. Lancet. 2003;361:358-359.
66. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;334:1255-1260.
67. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12:2288-2295.
68. Buyse M. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Nat Cancer Inst. 1996;88:252-258.
69. Earlam S, Glover C, Davies M, et al. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol. 1997;15:2022-2029.
70. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst. 1997;4:790-795.
71. Link K, Sunelaitis E, Kornmann M, et al. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid and mitomycin C may prolong survival. Cancer. 2001;92:2746-2753.
72. Heinrich S, Petrowsky H, Schwinnen I, et al. Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. Surgery. 2003;133:40-48.
73. Bartlett DL, Berlin J, Lauwers GY, et al. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1284-1292.
74. Nonami T, Takeuchi Y, Yasui M, et al. Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma. Semin Oncol. 1997;24:130-134.
75. Kemeny N, Huang Y, Cohen A, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999b;341:2039-2048.
76. Tono T, Hasuike Y, Ohzato H, et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer. 2000;88:1549-1556.
77. Shankar A, Leonard P, Renaut AJ, et al. Neo-adjuvant therapy improves resectability rates for colorectal liver metastases. Ann R Coll Surg Engl. 2001;83:85-88.
78. Khushalani NI, McKinley BP, Gibbs JF, et al. Regional chemotherapy is indicated after surgical resection of colorectal metastases to the liver: a debate. J Surg Oncol. 2003;82:65-72.
79. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1-7.
80. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007;14:3188-3194.
81. Xu J, Zhong Y, Weixin N, Xinyu Q, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg. 2007;245:583-590.
82. Morris-Stiff G, Tan YM, Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol. 2008;34:609-614.
83. White RR, Schwartz LH, Munoz JA, et al. Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol. 2008;97:601-604.
84. Goey SH, Eggermont AM, Oskam R, et al. Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: a phase I study. Ann Oncol. 1996;7:317-319.
85. Howell JD, Warren HW, Anderson JH, et al. Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer. Eur J Surg. 1999;165:652-658.
86. Okuno K, Yasutomi M, Kon M, et al. Intrahepatic interleukin-2 with chemotherapy for unresectable liver metastases: a randomized multi-center trial. Hepatogastroenterology. 1999;46:1116-1121.
87. Burke D, Davies MM, Zweit J, et al. Continuous angiotensin II infusion increases tumour normal blood flow ratio in colo-rectal liver metastases. Br J Cancer. 2001;85:1640-1645.
88. Cagol PP, Pasqual E, Bacchetti S. Potential advantages of loco-regional intra-arterial chemotherapy. In Vivo. 2006;20:777-779.
89. Bacchetti S, Pasqual E, Cagol PP. Epirubicin and its metabolites levels in experimental liver metastases after different administration routes. J Exp Clin Cancer Res. 2003;22:181-185.
90. Pasqual E, Bacchetti S, Cagol PP. Epiadryamicin concentration in experimental hepatic metastases after bolus or continous infusion through systemic or locoregional routes. J Exp Clin Cancer Res. 2003;22:229-232.
91. Kerr DJ, Ledermann JA, McArdle CS, et al. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol. 1995;13:2968-2972.
92. Arai Y, Inaba Y, Takeuchi Y, et al. Intermittent hepatic arterial infusion of high-dose 5-FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol. 1997;40:526-530.
93. Shankar A, Loizidou M, Burnstock G, et al. Noradrenaline improves the tumour to normal blood flow ratio and drug delivery in a model of liver metastases. Br J Surg. 1999;86:453-457.
94. Harmantas A, Rotstein L, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer. 1996;78:1639-1645.
95. Thirion P, Wolmark N, Haddad E, et al. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyes. Meta-Analysis Group in Cancer. Ann Oncol. 1999;10:1317-1320.
96. Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25:5649-5654.
97. Lorenz M, Muller H. Randomized multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243-254.
98. Kemeny M. The surgical aspects of the totally implantable hepatic artery infusion pump. Arch Surg. 2001;136:348-352.
99. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201:57-65.
100. Hildebrandt B, Pech M, Nicolaou A, et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a phase II - study and historical comparison with the surgical approach. BMC Cancer. 2007;24:7:69.
101. Sameshima S, Horikoshi H, Motegi K, et al. Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters. Eur J Surg Oncol. 2007;33:741-745.
102. Seki H, Ozaki T, Shiina M. Side-hole catheter placement for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer: long-term treatment and survival benefit. Am J Roentgenol. 2008;190:111-120.
103. Mathur P, Allen-Mersh TG. Hepatic arterial chemotherapy for colorectal liver metastases. Hepatogastroenterology. 2001;48:317-319.
104. Fiorentini G, De Giorgi U, Giovanis P, et al. Intra-arterial hepatic chemotherapy for liver metastases from colorectal cancer: need of guidelines for catheter positioning, port management and anticoagulant therapy. Ann Oncol. 2001;12:1023-1024.
105. Vauthey JN, Marsh W, Cendam C, et al. Arterial therapy of hepatic colorectal metastases. Br J Surg. 1996;83:447-455.
106. Jakob AR, Kuhl M, Jauch KW, et al. Complications using implantable port-systems for regional chemotherapy of liver metastases. Reg Cancer Treat. 1996;9:33-36.
107. Oberfield RA, McCaffrey JA, Polio J, et al. Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary. Cancer. 1979;44:414-423.
108. Okuyama K, Thonoso N, Koide Y, et al. Complications and their management in intra-arterial infusion chemotherapy. Gan To Kagaku Ryoho. 1992;19:1007-1013.
109. Laffer U, Durig M, Bloch HR, et al. Implantable catheter systems. Dtsch Med. 1989;114:655-658.
110. Huk I, Entscheff P, Prager M, et al. Patency rate of implantable devices during long-term intra-arterial chemotherapy. Angiology. 1990;41:936-941.
111. Dresing K, Lottner C, Stock W. Duodenal perforation of an intra-arterial port catheter and other complications following port implantation for regional cytostatic infusion of the liver. Med Klin. 1991;86:245-250.
112. Henne BD, Marks GH, Marks V, et al. Intra-arterial chemotherapy in the treatment of liver malignancies. Chirurg. 1989;114:668-676.
113. Mondini G, De Cian F, Balletto N, et al. Device performances and complications during hepatic arterial chemotherapy. Reg Cancer Treat. 1995;8:168-172.
114. Metzger U, Weder W, Rothlin M, et al. Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. Recent Results Cancer Res. 1991;121:198-204.
115. Liu LX, Zhang WH, Jiang HC, et al. Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. World J Gastroenterol. 2002;8:663-667.
116. Aldrighetti L, Arru M, Angeli E, et al. Percutaneous vs surgical placement of hepatic artery indwelling catheters for regional chemotherapy. Hepatogastroenterology. 2002;49:513-517.
117. Van Nieuwenhove Y, Aerts M, Neyns B, et al. Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases. Eur J Surg Oncol. 2007;33:336-340.
118. Germer CT, Boese LJ, Albrecht D, et al. The totally implantable minimally invasive hepatic artery catheter for intra-arterial chemotherapy of unresectable liver metastases in cases of dysfunction of arterial access devices. Chirurg. 1996;67:458-462.
119. Wacker F, Boese LJ, Wagner A, et al. Minimally invasive catheter implantation for regional chemotherapy of the liver: a new percutaneous transsubclavian approach. Cardiovasc Intervent Radiol. 1997;20:128-132.
120. Strecker E, Boos I, Ostheim DW, et al. Percutaneous implantable catheter-port system: preliminary technical results. Radiology. 1997;205:574-577.
121. Oi H, Kishimoto H, Matsushita M, et al. Percutaneous implantation of hepatic artery infusion reservoir by sonographically guided left subclavian artery puncture. Am J Roentgenol. 1996;166:821-822.
122. Herrmann KA, Waggershauser T, Sittek H, et al. Liver intra-arterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems. Radiology. 2000;215:294-299.
123. Zanon C, Grosso M, Clara R, et al. Combined regional and systemic chemotherapy by a mini-invasive approach for the treatment of colorectal liver metastases. Am J Clin Oncol. 2001;24:354-359.
124. Morandi C, Colopi S, Arai Y, et al. Percutaneous positioning of port catheter in the hepatic artery for chemotherapy of metastases using the Arai technique. Radiol Med. 1998;95:357-361.
125. Clouse ME, Ahmed R, Ryan RB, et al. Complications of long term transbrachial hepatic arterial infusion chemotherapy. Am J Roentgenol. 1977;129:799-803.
126. Cohen AM, Kaufman SD, Wood WC, et al. Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg. 1983;145:529-533.
127. Johnson LP, Wasserman PB, Rivkin SE. FUDR hepatic arterial infusions via an implantable pump for treatment of hepatic tumors. Proc Am Clin Oncol. 1983;1:337-344.
128. Weiss GR, Garnick MB, Osteen RT, et al. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol. 1983;1:337-344.
129. Niederhuber JE, Ensminger W, Gyves J, et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer. 1984;53:1336-1343.
130. Schwartz S, Jones LS, McCune CS. Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg. 1985;201:560-567.
131. Shepard KV, Levin B, Karl RC, et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol. 1985;3:161-169.
132. Balch CM, Urist MM. Intra-arterial chemotherapy for colorectal liver metastases and hepatomas using a totally implantable drug infusion pump. Recent Results Cancer Res. 1986;100:234-247.
133. Curley SA, Chase JL, Roh MS, et al. Technical considerations and complications associated with the placement of implantable hepatic arterial infusion devices. Surgery. 1993;114:928-935.
134. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685-693.
135. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7:1646-1654.
136. Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg. 1990;125:1022-1027.
137. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990;8:1885-1893.
138. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112-1118.